ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg may be appropriate for any patient with persistent diabetic macular edema (DME)

Consider ILUVIEN for the following patients with DME:

Consider ILUVIEN for phakic patients with DME, particularly those aged > 50 years and/or with developing cataracts

Patients with diabetes are 2 to 5 times more prone to cataract development2

In the ILUVIEN Phase 3 clinical trials:

  • 92% of patients were aged > 50 years3,4
  • 65% of all patients were phakic5
  • 83% of phakic patients had evidence of some cataract at baseline3

After cataract extraction, phakic patients treated with ILUVIEN had long-term VA outcomes similar to those observed in pseudophakic patients in the Phase 3 clinical trials6

FAME data: Patients gaining ≥ 15 letters based on lens status at baseline6

Pseudophakic1

Phakic > Pseudophakic during study1

Data from 48 patients who remained phakic throughout study are not shown in the graph or table.

Real-worldDATA
Real-world
DATA

Data from the USER Study confirm the efficacy of ILUVIEN
in a variety of patients with persistent DME.

PATIENTcase study
PATIENT
case study

See why Dr. Miller chose ILUVIEN for a
phakic patient in his practice.